Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.
about
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug developmentAnalysis of time to event outcomes in randomized controlled trials by generalized additive modelsGetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysis.A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study.Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Extrapolating Survival from Randomized Trials Using External Data: A Review of MethodsEstimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic ModelingCost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe diseaseMeta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes.Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-makingSurvival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.Predicting patient survival after deceased donor kidney transplantation using flexible parametric modelling.Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.Cost-effectiveness of a cardiac output-guided haemodynamic therapy algorithm in high-risk patients undergoing major gastrointestinal surgeryEstimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The NetherlandsReimbursement of licensed cell and gene therapies across the major European healthcare markets.Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges.Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility.Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study.Using Survival Analysis to Improve Estimates of Life Year Gains in Policy Evaluations.An Overview of R in Health Decision Sciences.Extrapolation of Survival Curves from Cancer Trials Using External Information.Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients.Bayesian Solutions for Handling Uncertainty in Survival Extrapolation.Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.Long-Term Survival Following Traumatic Brain Injury: A Population-Based Parametric Survival Analysis.Estimation of time-shift models with application to survival calibration in health technology assessment.Parametric multistate survival models: Flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences.Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
P2860
Q26866095-208E605B-A01F-4439-8EDA-858479CBA09CQ27309297-46BB62BF-91F0-42E6-995D-B93C49E2D1FEQ30248472-D8FA7555-68E7-4D73-BD69-DD43D9DA37A8Q30813204-01752EB4-0820-4D81-B066-91DC1E880DE9Q30914917-AC6DA399-3D47-414C-919F-A83C125189EFQ31056094-683608DD-D90B-4FD9-AC6E-7179AA44E940Q31064714-CCD21F1E-C458-4B2F-A12D-43F4F874D3FEQ31143912-ACC92DB1-57AB-4760-925B-8E00A7A70E40Q33413196-096FCCE4-9BE2-4C02-9F10-556B052544F8Q33654108-E427CA69-27DF-452A-BB8A-44A0A87AA166Q33656740-42098863-6427-437D-ADE0-A2346CB9CA21Q33684105-F8B3764D-6F0E-407C-8C8A-4E5A9A292588Q34436139-2EE9D8F0-6FDB-42B9-B1D6-D3A54D99DFFCQ35056525-D550FF91-C5A0-4590-B5DE-E45B1663903EQ35066875-5B78BD2A-8DBF-49A0-88BC-68524CCE934DQ35106391-88897DB3-B778-46A0-AD91-B104AEE0E4CEQ36029751-B85AB51C-9AD5-4E69-985D-09C05D70B64FQ36109802-A495E6AE-D520-47DD-AC06-9C872270CE49Q36177951-28FA9471-C61E-4F69-A312-5D1C397E1835Q36322923-CF142BD4-B5CB-499E-99E3-90BF259FD930Q36370297-1AFA89B7-5B6D-4862-AEA1-1F183E5240D6Q36380514-AB839BAD-DE64-431C-B0B3-BD8D5B16532CQ36714663-947059A4-708B-4344-8528-62A7B134C4B3Q37019499-6D1F1296-7AF0-428C-B981-8CB93CB9F683Q38218300-94375EC0-A61C-4A36-8F25-2B7F958C9C7DQ38228728-13ECEFC7-AD8F-4184-AD0A-A5899D4A3FBFQ38516032-01C45653-8AB0-4E36-B7E7-B9057834C786Q38692558-CD81320C-D1F5-4C29-8579-6F503F5FC930Q38722972-163623CB-DD35-488B-B3B1-A38003BEF86AQ38795635-044737CC-C33A-4C16-807D-638DC22D5E15Q38852135-B2FBFD41-5DA0-41DB-B1C1-F0D87827C8C4Q39070617-1C12823A-E7EA-49EE-83E5-11236E39550CQ39342401-323C9B15-45FD-46A0-A1B6-6ADC5C3F9119Q39647659-ACDCA806-1A9A-4067-893C-8AD049003A7BQ39696615-E7B1E0C4-E532-4277-B843-3CBAA021539AQ39737036-F07A662E-C234-482F-AF48-E01DA14FCCD6Q39778037-33CFA688-0E70-48BF-9767-35EC282E5230Q39870168-5BE9515F-6FB3-41DD-8848-3B174B99558DQ40057652-2ECCD538-46A8-4E0F-B91D-3135FCD4D20AQ40060071-57E15504-7DC7-4379-97AC-6C3440767081
P2860
Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Survival analysis for economic ...... ations, and a practical guide.
@ast
Survival analysis for economic ...... ations, and a practical guide.
@en
Survival analysis for economic ...... ations, and a practical guide.
@nl
type
label
Survival analysis for economic ...... ations, and a practical guide.
@ast
Survival analysis for economic ...... ations, and a practical guide.
@en
Survival analysis for economic ...... ations, and a practical guide.
@nl
prefLabel
Survival analysis for economic ...... ations, and a practical guide.
@ast
Survival analysis for economic ...... ations, and a practical guide.
@en
Survival analysis for economic ...... ations, and a practical guide.
@nl
P2860
P356
P1476
Survival analysis for economic ...... ations, and a practical guide.
@en
P2860
P304
P356
10.1177/0272989X12472398
P577
2013-01-22T00:00:00Z